|
|
|
|
|
|
Sponsored by: |
Peregrine Pharmaceuticals |
Information provided by: | Peregrine Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00687817 |
The primary objective of this study is to determine the overall response rate (complete response + partial response) to a combination of bavituximab plus carboplatin and paclitaxel in patients with previously untreated locally advanced or metastatic non-small cell lung cancer.
Condition | Intervention | Phase |
Non-Small Cell Lung Cancer |
Drug: bavituximab plus paclitaxel and carboplatin |
Phase II |
MedlinePlus related topics: | Cancer Lung Cancer |
ChemIDplus related topics: | Carboplatin Paclitaxel Bavituximab |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
Estimated Enrollment: | 49 |
Study Start Date: | June 2008 |
Estimated Study Completion Date: | May 2010 |
Estimated Primary Completion Date: | April 2010 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
Key Exclusion Criteria:
Contact: Smita Deshmukh, M.D. | 91-80-2808-2705 | smita.deshmukh@clinigeneintl.com |
Contact: Shweta Char, M.D. | 91-80-2808-2746 | shweta.char@clinigeneintl.com |
India | |||||
Apollo Hospital | Recruiting | ||||
Bangalore, India, 560 076 |
Peregrine Pharmaceuticals |
Responsible Party: | Peregrine Pharmaceuticals, Inc. ( Hayim Zadaca, Manager, Clinical Affairs ) |
Study ID Numbers: | PPHM 0701 |
First Received: | May 28, 2008 |
Last Updated: | July 14, 2008 |
ClinicalTrials.gov Identifier: | NCT00687817 |
Health Authority: | India: Drugs Controller General of India |
|
|
|
|
|